In the Summer of 2020, James T. Dalton, Ph.D. was named to the position of Executive Vice President and Provost at The University of Alabama in Tuscaloosa. Before that, Dalton served as the Dean and Professor of Pharmaceutical Sciences in the College of Pharmacy at the University of Michigan. He received his Bachelor of Science in Pharmacy from the University of Cincinnati (1986) and Doctor of Philosophy in pharmaceutics and pharmaceutical chemistry from Ohio State University (1990). Dean Dalton rose through the faculty ranks in the Department of Pharmaceutical Sciences in the College of Pharmacy at the University of Tennessee (1992-2000) before returning to Ohio State where he served as Professor and Chair in the Division of Pharmaceutics (2000-2007). He began an entrepreneurial leave of absence from Ohio State in 2005 and finally left OSU in 2007 to devote his full time effort as Chief Scientific Officer at GTx, Inc. in Memphis, TN (2007-2014) where he oversaw the preclinical and clinical development of selective androgen receptor modulators, which he will be talking about today. He was recently elected to the National Academy of Medicine and is a Fellow of the American Association for the Advancement of Science (AAAS) and American Association of Pharmaceutical Scientists (AAPS). He has co-authored over 300 original abstracts and peer-reviewed scientific manuscripts and is an inventor on over 400 United States and international patent applications related to selective androgen receptor modulators, selective estrogen receptor alpha and beta ligands, tubulin antagonists, and receptor tyrosine kinase inhibitors.